Three Bridge Wealth Advisors LLC Makes New $293,000 Investment in Immunome, Inc. (NASDAQ:IMNM)

Three Bridge Wealth Advisors LLC purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 27,615 shares of the company's stock, valued at approximately $293,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Stoneridge Investment Partners LLC purchased a new position in shares of Immunome in the 4th quarter worth about $123,000. AQR Capital Management LLC raised its stake in Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock valued at $194,000 after acquiring an additional 4,129 shares during the period. Intech Investment Management LLC bought a new stake in Immunome in the 3rd quarter valued at about $219,000. JPMorgan Chase & Co. raised its stake in Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock valued at $359,000 after acquiring an additional 1,520 shares during the period. Finally, XTX Topco Ltd bought a new stake in Immunome in the 3rd quarter valued at about $363,000. Institutional investors own 44.58% of the company's stock.

Immunome Stock Down 0.3 %

Shares of IMNM stock traded down $0.03 during trading on Friday, hitting $10.40. The company had a trading volume of 517,024 shares, compared to its average volume of 1,092,477. The stock's 50-day moving average is $10.91 and its two-hundred day moving average is $12.43. The stock has a market capitalization of $829.68 million, a price-to-earnings ratio of -1.28 and a beta of 1.90. Immunome, Inc. has a 52 week low of $8.97 and a 52 week high of $30.96.

Analyst Ratings Changes

A number of brokerages recently issued reports on IMNM. Wedbush restated an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, January 13th. Piper Sandler decreased their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Finally, Stephens began coverage on Immunome in a research report on Friday, November 8th. They set an "overweight" rating and a $30.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $28.60.

Insiders Place Their Bets

In other Immunome news, CTO Philip Tsai purchased 21,000 shares of the company's stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now directly owns 21,000 shares of the company's stock, valued at $198,030. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall purchased 66,057 shares of the company's stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average cost of $9.54 per share, with a total value of $630,183.78. Following the purchase, the chief executive officer now directly owns 485,693 shares of the company's stock, valued at $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 252,862 shares of company stock valued at $2,140,545 over the last quarter. 8.60% of the stock is owned by corporate insiders.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.